drugset
drugset / Trial / NCT00560716

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

NCT00560716 ↗

Phase 1 Terminated 25 enrolled Cyclacel Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.

Timeline

Start
2007-06
Primary completion
2009-01
Completion
2009-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject CYC116 Small molecule — Oral

Indications

cancer